Core 3: Patient Data
Core 3: Patient Data
批准号:
10713717
负责人:
Ana Ponce Kiess
金额:
$20.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-19 至 2028-08-31
关键词:
AdherenceAdoptionAgreementAlpha Particle EmitterClinical DataClinical ResearchCollaborationsDataData CollectionDatabasesDoseDrug KineticsERBB2 geneEthicsFOLH1 geneFutureGoalsImageIndustryJ591 Monoclonal AntibodyPatient imagingPatientsPositron-Emission TomographyPrivacyProtocols documentationRadiobiologyRadiopharmaceuticalsResearchResearch PersonnelScientific InquiryStandardizationToxic effectWorkabsorptiondata acquisitiondata sharingdosimetryflexibilityprogramsresponsesingle photon emission computed tomographystandard of caretreatment optimizationtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Overall, the primary effort of this Core will be to conduct a master imaging trial for patients undergoing RPT
treatment at Johns Hopkins, as well as to establish deep research collaborations among investigators,
collaborators and industry sponsors. For Aim 1, the Core Investigators will conduct a master imaging trial
(SeeToTreat) to acquire data for the P01 projects, with flexibility to include patients receiving standard of care or
research RPT on other protocols. For Aim 2, Dr. Sgouros, Dr. Kiess and the research staff have established
deep research collaborations with Bayer (227Th-HER2-TTC and 227Th-PSMA-TTC), Rayzebio (225Ac-
DOTATATE), and Cornell (225Ac-J591) to support the P01 Projects as well as future collaborative work. These
research collaborations will include sharing of images and data from completed and ongoing clinical studies,
including SPECT dosimetry, PET surrogate images and response data. The industry research agreements are
now fully executed. For Aims 3 and 4, the Core will establish a de-identified RPT database of images, absorbed
dose, tumor response and toxicity data. This will include collection of data from SEEtoTREAT, RAVENS, and
from industry and academic collaborators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金